Overview

Safety and Efficacy of SHPL-49 Injection in Participants With Acute Ischemic Stroke

Status:
COMPLETED
Trial end date:
2024-12-16
Target enrollment:
Participant gender:
Summary
This study is designed to determine the safety and efficacy of SHPL-49 intravenous infusion for 7 consecutive days in the treatment of acute ischemic stroke subjects.
Phase:
PHASE2
Details
Lead Sponsor:
Shanghai Hutchison Pharmaceuticals Limited
Collaborator:
Beijing Tiantan Hospital
Treatments:
Sodium Chloride